Financial support for these studies was provided by Roche, the Lymphoma and Leukemia Society, Friends of ANCHOR, an ASPET Astellas Award and grants from the National Institutes of Health, National Cancer Institute (CA189477, CA121938, CA155620). National Cancer Institute (NCI) Therapeutic Training Grant 5T32CA121938, NIH/NCI Research Grants R21 CA189477, an ASPET David Lehr Award and the Padres Pedal the Cause #PTC2017 award.Peer reviewedPublisher PD

Corriden, Ross

Feigin, Michael

French, Randall P.

Insel, Paul A.

Katakia, Trishna

Liu, Dongling

Lowy, Andrew M.

McCann, Thalia

Murray, Fiona

Sriram, Krishna

Wilderman, Andrea

Wiley, Shu Z.

Yokouchi, Hiroshi

Zhang, Lingzhi

Frontiers in Pharmacology

Paul A. Insel

Krishna Sriram

Shu Z. Wiley

Andrea Wilderman

Trishna Katakia

Thalia McCann

Hiroshi Yokouchi

Lingzhi Zhang

Ross Corriden

Dongling Liu

Michael E. Feigin

Randall P. French

Andrew M. Lowy

Fiona Murray

Frontiers - Publisher Connector

GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets

Financial support for these studies was provided by Roche, the Lymphoma and Leukemia Society, Friends of ANCHOR, an ASPET Astellas Award and grants from the National Institutes of Health, National Cancer Institute (CA189477, CA121938, CA155620). National Cancer Institute (NCI) Therapeutic Training Grant 5T32CA121938, NIH/NCI Research Grants R21 CA189477, an ASPET David Lehr Award and the Padres Pedal the Cause #PTC2017 award.Peer reviewe

Aberdeen University Research

GPCRomics : GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets

Crossref

G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive tumors. Limited knowledge regarding GPCR expression in cancer cells likely has contributed to this lack of use of GPCR-targeted drugs as cancer therapeutics. We thus undertook GPCRomic studies to define the expression of endoGPCRs (which respond to endogenous molecules such as hormones, neurotransmitters and metabolites) in multiple types of cancer cells. Using TaqMan qPCR arrays to quantify the mRNA expression of ∼340 such GPCRs, we found that human chronic lymphocytic leukemia (CLL) cells/stromal cells associated with CLL, breast cancer cell lines, colon cancer cell lines, pancreatic ductal adenocarcinoma (PDAC) cells, cancer associated fibroblasts (CAFs), and PDAC tumors express 50 to &gt;100 GPCRs, including many orphan GPCRs (which lack known physiologic agonists). Limited prior data exist regarding the expression or function of most of the highly expressed GPCRs in these cancer cells and tumors. Independent results from public cancer gene expression databases confirm the expression of such GPCRs. We propose that highly expressed GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and GPR68 in PDAC CAFs) may contribute to the malignant phenotype, serve as biomarkers and/or may be novel therapeutic targets for the treatment of cancer

Insel, Paul

Wiley, Shu

French, Randall

Lowy, Andrew

eScholarship - University of California

GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.

https://aura.abdn.ac.uk/bitstream/handle/2164/10478/fphar_09_00431.pdf?sequence=1&isAllowed=y

GPCRomics : GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets

Abstract

Similar works

Full text

Available Versions

Frontiers - Publisher Connector

Aberdeen University Research

Crossref

eScholarship - University of California